Despite revenue growth, the share price drop may signal unresolved issues. The company's performance, worse than the 5% annualised loss over the last half decade, could be a bad omen. Contrarian investors might see a potential turnaround.

Insider selling activity might concern shareholders and the lack of insider buying over the past year adds to this worry. Despite some alignment due to insider ownership, the history of sales necessitates caution before buying company shares.

The partnership with Ora Medical strengthens OrthoPediatric's non-surgical offerings, enhancing their mobility solutions portfolio. Ora views it as a key step in expanding beyond Canada, supported by OrthoPediatrics' market presence and expertise.